Safety, Pharmacokinetics and Pharmocodynamics of Recombinant Human Porphobilinogen Deaminase in Healthy Subjects and Asymptomatic Carriers of the Acute Intermittent Porphyria Gene Who Have Increased…

Overview of attention for article published in Clinical Pharmacokinetics, September 2012

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

patent: 7 patents

Citations

dimensions_citation: 41 Dimensions

Readers on

mendeley: 34 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 7 patents that reference this research output.

Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof

Grant US-11390854-B2

United States of America

Compositions and methods for inhibiting expression of the ALAS1 gene

Grant US-11028392-B2

United States of America

Compositions and methods for inhibiting expression of the ALAS1 gene

Grant US-10400239-B2

United States of America

Compositions and methods for inhibiting expression of the ALAS1 gene

Application US-10125364-B2

United States of America

Compositions and methods for inhibiting expression of the ALAS1 gene

Application US-10119143-B2

United States of America

Compositions and methods for inhibiting expression of the ALAS1 gene

Grant US-9631193-B2

United States of America

Compositions and methods for inhibiting expression of the ALAS1 gene

Grant US-9133461-B2

United States of America